<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33428242</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Melatonin may slow disease progression in amyotrophic lateral sclerosis: Findings from the Pooled Resource Open-Access ALS Clinic Trials database.</ArticleTitle><Pagination><StartPage>572</StartPage><EndPage>576</EndPage><MedlinePgn>572-576</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27168</ELocationID><Abstract><AbstractText Label="INTRODUCTION">We utilized the Pooled Resource Open-Access Clinical Trials (PRO-ACT) database to investigate whether melatonin use among patients with amyotrophic lateral sclerosis (ALS) was associated with slower disease progression and prolonged survival.</AbstractText><AbstractText Label="METHODS">This retrospective analysis of the PRO-ACT database addresses the impact of melatonin on progression and overall survival of ALS. A Cox proportional hazards ratio model was performed to investigate the effect that melatonin had on time to death. For secondary outcome measures, linear mixed effects regression models were used to ascertain the effect of melatonin on change in standardized ALS Functional Rating Scale (sALSFRS) and percentage predicted forced vital capacity (FVC) scores.</AbstractText><AbstractText Label="RESULTS">Melatonin users had a significantly decreased annualized hazard death rate compared with the non-melatonin users (hazard ratio, 0.241; 95% confidence interval, 0.088-0.659; P = .0056). The melatonin users also had a slower rate of decline in sALSFRS score (t = 2.71; P = .0069) and change in percent predicted FVC score (t = 2.94; P = .0035) compared with the non-melatonin users.</AbstractText><AbstractText Label="DISCUSSION">Our findings suggest that melatonin may be beneficial for patients with ALS. Due to the nature of this database, our results are solely intended to be hypothesis-generating and no strong associations can be made. Given the low cost and favorable safety profile of melatonin, the hypotheses generated warrant further investigation.</AbstractText><CopyrightInformation>&#xa9; 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bald</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nance</LastName><ForeName>Christopher S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Carver College of Medicine at the University of Iowa, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Jordan L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Carver College of Medicine at the University of Iowa, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 NS117736</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="N">Melatonin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">PRO-ACT</Keyword><Keyword MajorTopicYN="N">disease progression</Keyword><Keyword MajorTopicYN="N">melatonin</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList><CoiStatement><b>Disclosure of Conflicts of Interest:</b> None of the authors has any conflict of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>11</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33428242</ArticleId><ArticleId IdType="mid">NIHMS1776367</ArticleId><ArticleId IdType="pmc">PMC8842494</ArticleId><ArticleId IdType="doi">10.1002/mus.27168</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lacomblez L, Bensimon G, Meininger V, Leigh P, Guillet P. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. The Lancet. 1996;347(9013):1425&#x2013;1431. doi:10.1016/s0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. N Engl J Med. 1994;330(9):585&#x2013;591. doi:10.1056/nejm199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;512. doi:10.1016/s1474-4422(17)30115-1.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(17)30115-1.2</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol. 1998;56(3):359&#x2013;384. doi:10.1016/s0301-0082(98)00052-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0301-0082(98)00052-5</ArticleId><ArticleId IdType="pubmed">9770244</ArticleId></ArticleIdList></Reference><Reference><Citation>Alghamdi BS. The neuroprotective role of melatonin in neurological disorders. J Neurosci Res. 2018;96(7):1136&#x2013;1149. doi:10.1002/jnr.24220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24220</ArticleId><ArticleId IdType="pmc">PMC6001545</ArticleId><ArticleId IdType="pubmed">29498103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013;8(4):888&#x2013;899. doi:10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber SC, Shaw PJ. Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48(5):629&#x2013;641. doi:10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollari E, Goldsteins G, Bart G, Koistinaho J, Giniatullin R. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front Cell Neurosci. 2014;8:131. Published 2014 May 13. doi:10.3389/fncel.2014.00131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00131</ArticleId><ArticleId IdType="pmc">PMC4026683</ArticleId><ArticleId IdType="pubmed">24860432</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(5&#x2013;6):414&#x2013;425. doi:10.3109/21678421.2016.1140786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1140786</ArticleId><ArticleId IdType="pmc">PMC4950444</ArticleId><ArticleId IdType="pubmed">26864085</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2008:1&#x2013;14. doi:10.1080/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AA, Fournier C, Polak M, et al. Predicting disease progression in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2016;3(11):866&#x2013;875. doi:10.1002/acn3.348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.348</ArticleId><ArticleId IdType="pmc">PMC5099532</ArticleId><ArticleId IdType="pubmed">27844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46:399&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Cook A, Kim J, et al. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2013;55:26&#x2013;35. doi:10.1016/j.nbd.2013.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.03.008</ArticleId><ArticleId IdType="pmc">PMC3652329</ArticleId><ArticleId IdType="pubmed">23537713</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt JH, Bartels C, P&#xf6;lking E, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res. 2006;41(4):313&#x2013;323. doi:10.1111/j.1600-079x.2006.00377.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079x.2006.00377.x</ArticleId><ArticleId IdType="pubmed">17014688</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Panayiotou E, Feldman ML, et al. Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration. Neurosci Lett. 2013;548:170&#x2013;175. doi:10.1016/j.neulet.2013.05.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.05.058</ArticleId><ArticleId IdType="pubmed">23748038</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole But Not Melatonin Ameliorates Acute Motor Neuron Degeneration and Moderately Inhibits SOD1-Mediated Excitotoxicity Induced Disrupted Mitochondrial Ca2 Signaling in Amyotrophic Lateral Sclerosis. Front Cell Neurosci. 2017;10. doi:10.3389/fncel.2016.00295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2016.00295</ArticleId><ArticleId IdType="pmc">PMC5216043</ArticleId><ArticleId IdType="pubmed">28111541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob S, Poeggeler B, Weishaupt JH, et al. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. J Pineal Res. 2002;33(3):186&#x2013;187. doi:10.1034/j.1600-079x.2002.02943.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-079x.2002.02943.x</ArticleId><ArticleId IdType="pubmed">12220335</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>